{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009315","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.511204+00:00","generated_at":"2026-06-25T21:01:27.979020+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"David Johnson appointed to Caribou board; brings 30 years biopharma commercial experience","bullets":["Board expanded from 7 to 8 directors; Johnson appointed effective May 11, 2022.","Annual cash compensation of $40,000; initial option for 44,000 shares vesting over 3 years.","Johnson was CCO at Global Blood Therapeutics and spent 15 years at Gilead in commercial roles.","No immediate committee assignments; standard indemnification agreement entered."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009315","json":"https://secwatch.observer/filing/0000950170-22-009315.json","markdown":"https://secwatch.observer/filing/0000950170-22-009315.md","text":"https://secwatch.observer/filing/0000950170-22-009315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/0000950170-22-009315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/crbu-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:01:27.979020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e55f4238c","claim":"David L. Johnson was appointed as Class II director at Caribou Biosciences, Inc..","evidence_excerpt":"increased the size of the Board from seven to eight directors and unanimously agreed to extend an offer to David L. Johnson, M.B.A., to serve as a Class II director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/0000950170-22-009315-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}